RECURSION PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Deferred Income Tax Expense (Benefit) of -$4.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$3.00K, a 100.47% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$4.60M.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-06-30 was $638.00K.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2025-03-31 was -$419.00K.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was -$368.00K.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was -$1.63M.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was -$4.06M.
- RECURSION PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.60M 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | -$4.60M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | -$368.00K 10-K · filed 2026-02-25 | |||
| 2025-06-30 | $638.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $219.00K 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | -$419.00K 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$1.63M 10-K · filed 2026-02-25 | -$1.63M 10-K · filed 2025-02-28 | ||
| 2023-12-31 | -$4.06M 10-K · filed 2026-02-25 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |